Does this transcript contain new financial guidance?

No. The document is a formal record of the May 22 earnings call and contains no information that was not already disseminated to the market.

Why is this filing being released now?

It is a procedural requirement to provide a regulatory record of the earnings conference call held on May 22, 2026.

Earnings · Pharmaceuticals · Small cap

IOL Chemicals files transcript of May 22 earnings call

The document is a formal record of management's commentary on FY27 guidance and capex, but contains no new information.

— 3 earlier stories on IOL Chemicals And Pharmaceuticals Ltd. →

IOLCP 28 May 2026 · 6:49 PM IST Verify on BSE · NSE

Mkt cap₹3,855 cr

P/E28.01×

ROE5.99%

Debt / eq.0.07

Div yld0.76%

N/A No new financial data or material disclosures.

What's new

IOL Chemicals filed the transcript for its May 22 earnings call.
The document covers FY27 revenue guidance and paracetamol capacity targets.
The filing is a routine record and contains no information not already public.

Why this matters

This is a routine regulatory record. It offers no incremental surprise to the market beyond what was already disclosed in the initial earnings summary.

What we're watching

Progress on long-term greenfield capex projects.
Actual capacity utilization rates in the paracetamol segment.
Updates on FY27 revenue targets in future disclosures.

The full read

IOL Chemicals and Pharmaceuticals has filed the formal transcript of its earnings conference call held on May 22, 2026. The document provides a record of the discussion regarding the company's performance for the fiscal year ended March 31, 2026. Management addressed several key areas during the call, including FY2027 revenue guidance, capacity utilization targets for the paracetamol segment, and the status of ongoing greenfield capital expenditure. Because a summary of this call was already provided in a prior filing, this transcript contains no incremental information or surprises for the market. It is a routine regulatory disclosure.

Questions answered

Does this transcript contain new financial guidance?: No. The document is a formal record of the May 22 earnings call and contains no information that was not already disseminated to the market.
What topics did management discuss during the call?: Management discussed FY2027 revenue guidance, capacity utilization targets for the paracetamol segment, and the progress of long-term greenfield capex.
Why is this filing being released now?: It is a procedural requirement to provide a regulatory record of the earnings conference call held on May 22, 2026.

Mentioned: IOL Chemicals and Pharmaceuticals · May 22, 2026

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on IOLCP →

28 May 2026 · 6:49 PM IST IOL Chemicals files transcript of May 22 earnings call
6d ago IOL Chemicals misses paracetamol capacity target as it plans ₹1,400 cr capex
7d ago IOL Chem's Q4 & FY26 results: Old news, no surprises
8d ago IOL Chemicals hits record Q4 revenue of ₹619.5 cr, PAT up 68%